Originally from Swansea in Wales, Dr Andrew Lewis graduated with his PhD from the University of Cambridge in 2013 under the supervision of Professor Sir Shankar Balasubramanian. During his PhD he worked on the synthesis and biological understanding of quinone containing natural products and their use as anticancer agents. Prior to this, Andrew read Natural Sciences at St Catharine's College, University of Cambridge completing his MSc with Professor Steven Ley working on the synthesis of novel hydrogen bond organocatalysts.
From 2013 to 2016 Andrew worked as a postdoctoral fellow at the University of Toronto with Professor Patrick Gunning working on the design and synthesis of protein-protein interaction inhibitors and using chemical biological techniques to understand their mode of action. After moving back to the UK in 2016 Andrew joined the Huber group at the Target Discovery Institute, University of Oxford where his research involved the use of chemical biology and chemoproteomic techniques to identify novel drug targets for multiple myeloma.
In October 2019 Andrew joined Manchester Metropolitan University as a lecturer in chemical biology where his group focuses on developing chemical tools to understand protein-protein interactions
2008-2012 PhD - CRUK Graduate Training Programme in Medicinal Chemistry, University of Cambridge
Supervisor: Professor Sir Shankar Balasubramanian
2007-2008 MSci Chemistry, University of Cambridge
Supervisor: Professor Steve Ley
2016-2019 Postdoctoral Research Fellow, Target Discovery Institute, University of Oxford
Supervisor: Dr Kilian Huber
2013-2016 Postdoctoral Research Fellow, University of Toronto
Supervisor: Professor Patrick Gunning
S. Scheer, S. Ackloo, TS. Medina, M. Schapira, F. Li, et al. (2019). A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. Nature Communications. 10(1),
V. Fagan, C. Johansson, C. Gileadi, O. Monteiro, JE. Dunford, et al. (2019). A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function. Journal of medicinal chemistry.
J. Stefaniak, AM. Lewis, D. Conole, SRG. Galan, CJR. Bataille, et al. (2018). Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors. ACS Chemical Biology. 13(10), pp.2849-2854.
S. Scheer, S. Ackloo, T. Medina, M. Schapira, F. Li, et al. (2018). A Chemical Biology Toolbox for the Study of Protein Methyltransferases and Epigenetic Signaling. bioRxiv.
SR. da Silva, S-L. Paiva, M. Bancerz, M. Geletu, AM. Lewis, et al. (2016). A selective inhibitor of the UFM1-activating enzyme, UBA5. Bioorganic & medicinal chemistry letters. 26(18), pp.4542-4547.
DP. Ball, AM. Lewis, D. Williams, D. Resetca, DJ. Wilson, et al. (2016). Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent. Oncotarget. 7(15), pp.20669-20679.
S. Haftchenary, AO. Jouk, I. Aubry, AM. Lewis, M. Landry, et al. (2015). Identification of Bidentate Salicylic Acid Inhibitors of PTP1B. ACS medicinal chemistry letters. 6(9), pp.982-986.
M. Singh, N. Garg, C. Venugopal, R. Hallett, T. Tokar, et al. (2015). STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget. 6(29), pp.27461-27477.
AA. Cumaraswamy, AM. Lewis, M. Geletu, A. Todic, DB. Diaz, et al. (2014). Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein. ACS Medicinal Chemistry Letters. 5(11), pp.1202-1206.
BDG. Page, DC. Croucher, ZH. Li, S. Haftchenary, VH. Jimenez-Zepeda, et al. (2013). Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. Journal of medicinal chemistry. 56(18), pp.7190-7200.
AM. Lewis, DP. Ball, R. Rana, JS. Park, D. Rosa, et al. (2015). Developing Inhibitors of STAT3: Targeting Downstream of the Kinases for Treating Disease. In: Kinomics. Wiley-VCH Verlag GmbH & Co. KGaA, pp.281-300.